LCTX Historical PE Ratio Notes

— Lineage Cell Therapeutics (ticker symbol LCTX) is a clinical-stage biotechnology company focused on developing novel cell therapies for the treatment of serious diseases such as spinal cord injuries, dry age-related macular degeneration (dry AMD), & certain cancers. The company leverages its proprietary cell-based technology platforms to regenerate or replace dysfunctional cells, offering potential disease-modifying treatments rather than just symptom management. When reviewing the historical price-earnings (PE) ratio for LCTX, it’s essential to note that, like many early-stage biotech firms, the company typically does not generate meaningful revenue or earnings, as most of its value lies in future therapeutic potential rather than current profitability. As a result, historical PE ratios for LCTX may be extremely high or undefined (when earnings are negative or zero), reflecting both ongoing research & development expenses & investor speculation on the potential of its science to yield successful, marketable therapies. While these characteristics can lead to high share price volatility & nontraditional PE ratio patterns over time, movements in the stock price are often more closely tied to clinical trial progress, partnerships, & regulatory milestones than to traditional financial metrics like earnings per share.

On this page we presented the LCTX Historical PE Ratio information for Lineage Cell Therapeutics' stock. The average LCTX historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 43.8. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average LCTX historical PE based on this TTM earnings result method is 3.2. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this LCTX historical PE result, against the recent PE: when this page was posted on 8/14/2026, the most recent closing price for LCTX had been 1.07, and the most recent quarterly earnings result, annualized, was 0.016. Meanwhile, the most recent TTM earnings summed to 0.27. From these numbers, we calculate the recent LCTX PE on 8/14/2026 based on annualized quarterly EPS was 66.9. Based on LCTX's history, that recent PE is elevated relative to the historical average, with the recent PE 52.7% higher than the historical average PE across our data set for Lineage Cell Therapeutics. Looking at the recent LCTX PE on 8/14/2026 based on TTM EPS, we calculate the ratio at 4.0. Based on LCTX's history, that recent PE is elevated relative to the historical average, with the recent PE 25.0% higher than the historical average PE across our Lineage Cell Therapeutics data set with TTM EPS used in the calculation at each period.

For self directed investors doing their due diligence on LCTX or any other given stock, valuation analysis for LCTX can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Lineage Cell Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for LCTX. Thanks for visiting, and the next time you need to research LCTX Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.